EDQM – Notification to CEP holders: Implementation of the European Pharmacopoeia Supplement 10.7

In October 2021, the EDQM (European Directorate for the Quality of Medicines and Healthcare) [...]

Ler mais

EMA – Concern on the safety of titanium dioxide could result in reformulation of drug products in Europe (updated on August 10, 2022)

Since 2020, titanium dioxide (TiO2) has been the subject of concern about its safety for use as [...]

Ler mais

EMA – Update of Pre-authorisation guidance for users of the centralised procedure

In July and September, the authority EMA (European Medicines Agency) updated the document [...]

Ler mais

EMA – Update of Pre-authorisation guidance for users of the centralised procedure

In July and September, the authority EMA (European Medicines Agency) updated the document [...]

Ler mais

EDQM – Notification to CEP holders: Implementation of the European Pharmacopoeia Supplement 10.6

In July 2021, the EDQM (European Directorate for the Quality of Medicines and Healthcare) [...]

Ler mais

EMA – Update of the Document Regulatory Q&A on Herbal Medicinal Products

In August 2021, the European Medicines Agency-EMA published an update of the regulatory [...]

Ler mais

EMA – Update of the Guideline on post-authorisation procedural advice for users of the centralised procedure

In July, the European Medicines Agency (EMA) has updated its Guideline on post-authorisation [...]

Ler mais

Whitepaper – Differences between CADIFA (Letter of Suitability of the Active Pharmaceutical Ingredient) – ANVISA and CEP (Certificate of Suitability) – EDQM

In April 2021, the New Regulatory Framework for APIs in Brazil completed one year since its [...]

Ler mais

EMA – Review of the Question and Answer Documents for Centralized Procedure

On February 2021, the European Medicines Agency (EMA) published on its website an updated [...]

Ler mais

Whitepaper: Diffferences between CTD Brazil and UE: a look at CMC requirements

Our daily lives at Vita are full of discussions about technical and regulatory differences in [...]

Ler mais

EMA publishes Questions and Answers document on Brexit

On January 1, 2021, the United Kingdom (UK) will be considered a “third country” [...]

Ler mais

EMA – Pilot programme for international cooperation in GMP inspection of manufacturers of sterile medicinal products for human use

The European Medicines Agency (EMA) and its European and international partners launched a [...]

Ler mais

Subscribe to our Newsletter

    Select the language to receive our newsletter

    PortugueseEnglish